Peptides for men's health on TikTok: what the evidence actually shows

What's this video probably claiming?

Based on the caption and hashtags, Dr. Anika Ackerman, a urologist on TikTok, is likely walking viewers through a list of prescription peptides or peptide-adjacent compounds she considers useful for men's health conditions. Given the explicit mention of erectile dysfunction and Peyronie's disease alongside the peptide category tag, the video almost certainly discusses agents like BPC-157, TB-500, or possibly PT-141 (bremelanotide) in the context of sexual function. There may also be mention of growth hormone secretagogues like CJC-1295 or ipamorelin for general male vitality, body composition, or recovery. The framing, 'my go-to prescription options,' implies these are being positioned as legitimate clinical tools rather than experimental compounds, which is a significant claim that deserves scrutiny. Physician-created content on TikTok consistently draws large audiences partly because the credential adds implied authority, making it especially important to separate what sounds plausible from what the data actually supports.

What does the science actually show?

The honest answer is: very little, at least in humans. BPC-157 has shown tissue repair and anti-inflammatory effects in rodent models (Seiwerth et al., 2018, Current Pharmaceutical Design), but zero completed randomized controlled trials in humans exist as of 2024. TB-500 (thymosin beta-4) similarly has preclinical wound-healing data but no human efficacy trials for ED or connective tissue repair in Peyronie's plaques. PT-141, by contrast, is FDA-approved as bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, with a Phase 2 trial showing statistically significant improvement in desire scores versus placebo (Simon et al., 2014, Journal of Sexual Medicine), but its off-label use in men with ED has only small, industry-affiliated studies behind it. For Peyronie's disease specifically, the only FDA-approved injectable is collagenase clostridium histolyticum (Xiaflex), supported by the IMPRESS trials showing roughly 34% reduction in penile curvature (Gelbard et al., 2013, Journal of Urology). Peptides have not been tested against that benchmark.

Where does the social media noise diverge from clinical reality?

The gap is wide. Calling compounded peptides 'prescription options' for Peyronie's disease implies a level of regulatory standing these compounds do not have. The FDA placed BPC-157 and TB-500 on its list of bulk drug substances that cannot be compounded under Section 503A and 503B, effective 2024, which means compounding pharmacies are no longer legally permitted to produce them for patient use in the US. That is not a technicality, it is a material fact any prescribing physician should be leading with. Growth hormone secretagogues like CJC-1295 and ipamorelin are also not FDA-approved; they exist in a compounding gray zone that is shrinking. Meanwhile, the benefits being discussed, improved sexual function, plaque reduction, tissue regeneration, are extrapolated from animal data or anecdote. A 2023 systematic review in Andrology (Patel et al.) found insufficient evidence to recommend any peptide therapy for male sexual dysfunction. Social media compresses that nuance into a confident list format that can mislead patients into pursuing compounds with real cost, injection burden, and unknown long-term safety profiles.

What should you actually know?

If you have ED or Peyronie's disease, the evidence-based treatment ladder is well established and should be your first conversation with a provider. For ED, PDE5 inhibitors like sildenafil and tadalafil have decades of safety data and consistent efficacy across thousands of trials. For Peyronie's, Xiaflex injections, penile traction therapy, and in some cases surgery represent the standard of care with documented outcomes. Peptide therapies for these conditions are not supported by sufficient human data to justify confident clinical recommendation, particularly when regulatory access is being tightened. That said, legitimate research is ongoing. PT-141 has real mechanistic plausibility for men with psychogenic ED or desire issues, and a proper trial is warranted. If you see a TikTok physician presenting a peptide list as a clinical menu, the right question is: what Phase 2 or Phase 3 human trial are you pulling from? If the answer is a rat study or a compounding pharmacy protocol sheet, that is not a prescription option. That is an experiment.